
|Articles|December 17, 2013
- Melanoma (Issue 1)
- Volume 1
- Issue 1
The Treatment of Melanoma With Emerging Targeted Therapies
Author(s)Georgina Long, BSc, PhD, MBBS, FRACP
Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses the treatment of melanoma with emerging targeted therapies.
Advertisement
Articles in this issue
almost 12 years ago
Two BRAF Fusions Discovered in Some Pan-Negative Melanomasalmost 12 years ago
Understanding the Biologic Pathways in Basal Cell Carcinomaalmost 12 years ago
Advances in Metastatic Melanomaabout 12 years ago
Targeted Therapies in Basal Cell Carcinomaabout 12 years ago
The Outlook for BRAF Inhibitors in MelanomaAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5







































